Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Global | Publication | April 2024
The insurance industry is founded on predicting, as accurately as possible, whether or not a risk will materialize in a fast-moving competitive environment. Such predictions are intensively focused on data.
AI promises new insights by analyzing more data points, simultaneously across multiple data sets, leading to automation of complex cognitive processes. However, this comes with risks. Without regulation, AI models can replicate and reinforce bias of the past, with no regard for current social constraints or indeed long-term social cohesion.
For governments to achieve the benefits of AI adoption they need to ensure that society trusts in such AI, through safeguards in design, operation and management of the models, as well as accountability for AI operators when things go wrong.
However, where regulatory approaches diverge across jurisdictions, in practice, international businesses may be forced to respond to the highest standards, regardless of the differing levels of country-specific intervention.
AI is transforming the insurance industry by enabling automation of repetitive tasks and generating insights from large data sets. Some applications by insurers include:
Given the wide range of use cases in which AI can be deployed, governments across the world have sought to articulate clear rules to guide those developing or deploying AI. This piece briefly summarizes the current regulatory state of play in the insurance sector in the EU, Germany, UK, Singapore, US, and Australia.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023